EP
TCRX icon

Essential Partners’s TScan Therapeutics TCRX Stock Holding History

Essential Partners’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11
Closed -$16 – 2786
2025
Q2 		$16 Buy
+11
New +$16 ﹤0.01% 2236

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Essential Partners's TCRX Position: Q3 2025 in Review

Essential Partners sold out of TScan Therapeutics (TCRX) in Q3 2025, closing a stake of 11 shares — an estimated $16 sold.

Essential Partners first reported a position in TCRX in Q2 2025 and held it in 1 quarter. The position peaked at $16 in Q2 2025. 73 funds tracked by Wall St. Rank hold TCRX as of Q3 2025.

  • Essential Partners reported no remaining TScan Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Essential Partners sold 11 TScan Therapeutics shares in Q3 2025, an estimated $16.
  • Essential Partners first reported a position in TScan Therapeutics in Q2 2025 and held it in 1 quarter.
  • Essential Partners's TScan Therapeutics position peaked at $16 in Q2 2025.
  • 73 funds tracked by Wall St. Rank held TScan Therapeutics as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.